Chun-kai Huang1,2, Bi-yi Chen2, Ang Guo2, Rong Chen1,2, Yan-qi Zhu1,2, William Kutschke2, Jiang Hong1, Long-sheng Song2,3. 1. Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China. 2. Division of Cardiovascular Medicine, Department of Internal Medicine, University of Iowa, Carver College of Medicine, Iowa City, IA 52242, USA. 3. Department of Veterans Affairs Medical Center, Iowa City, IA 52242, USA.
Abstract
AIM: Sildenafil, a phosphodiesterase 5 (PDE5) inhibitor, has been shown to exert beneficial effects in heart failure. The purpose of this study was to test whether sildenafil suppressed transverse-tubule (T-tubule) remodeling in left ventricular (LV) failure and thereby providing the therapeutic benefits. METHODS: A pressure overload-induced murine heart failure model was established in mice by thoracic aortic banding (TAB). One day after TAB, the mice received sildenafil (100 mg·kg(-1)·d(-1), sc) or saline for 5 weeks. At the end of treatment, echocardiography was used to examine LV function. Then the intact hearts were dissected out and placed in Langendorff-perfusion chamber for in situ confocal imaging of T-tubule ultrastructure from epicardial myocytes. RESULTS: TAB surgery resulted in heart failure accompanied by remarkable T-tubule remodeling. Sildenafil treatment significantly attenuated TAB-induced cardiac hypertrophy and congestive heart failure, improved LV contractile function, and preserved T-tubule integrity in LV cardiomyocytes. But sildenafil treatment did not significantly affect the chamber dilation. The integrity of LV T-tubule structure was correlated with cardiac hypertrophy (R(2)=0.74, P<0.01) and global LV function (R(2)=0.47, P<0.01). CONCLUSION: Sildenafil effectively ameliorates LV T-tubule remodeling in TAB mice, revealing a novel mechanism underlying the therapeutic benefits of sildenafil in heart failure.
AIM: Sildenafil, a phosphodiesterase 5 (PDE5) inhibitor, has been shown to exert beneficial effects in heart failure. The purpose of this study was to test whether sildenafil suppressed transverse-tubule (T-tubule) remodeling in left ventricular (LV) failure and thereby providing the therapeutic benefits. METHODS: A pressure overload-induced murineheart failure model was established in mice by thoracic aortic banding (TAB). One day after TAB, the mice received sildenafil (100 mg·kg(-1)·d(-1), sc) or saline for 5 weeks. At the end of treatment, echocardiography was used to examine LV function. Then the intact hearts were dissected out and placed in Langendorff-perfusion chamber for in situ confocal imaging of T-tubule ultrastructure from epicardial myocytes. RESULTS:TAB surgery resulted in heart failure accompanied by remarkable T-tubule remodeling. Sildenafil treatment significantly attenuated TAB-induced cardiac hypertrophy and congestive heart failure, improved LV contractile function, and preserved T-tubule integrity in LV cardiomyocytes. But sildenafil treatment did not significantly affect the chamber dilation. The integrity of LV T-tubule structure was correlated with cardiac hypertrophy (R(2)=0.74, P<0.01) and global LV function (R(2)=0.47, P<0.01). CONCLUSION:Sildenafil effectively ameliorates LV T-tubule remodeling in TABmice, revealing a novel mechanism underlying the therapeutic benefits of sildenafil in heart failure.
Authors: J A Hill; M Karimi; W Kutschke; R L Davisson; K Zimmerman; Z Wang; R E Kerber; R M Weiss Journal: Circulation Date: 2000-06-20 Impact factor: 29.690
Authors: N B Schiller; H Acquatella; T A Ports; D Drew; J Goerke; H Ringertz; N H Silverman; B Brundage; E H Botvinick; R Boswell; E Carlsson; W W Parmley Journal: Circulation Date: 1979-09 Impact factor: 29.690
Authors: Eunkyung Lee; Melissa Marcucci; Laurie Daniell; Marc Pypaert; Ora A Weisz; Gian-Carlo Ochoa; Khashayar Farsad; Markus R Wenk; Pietro De Camilli Journal: Science Date: 2002-08-16 Impact factor: 47.728
Authors: William E Louch; Virginie Bito; Frank R Heinzel; Regina Macianskiene; Johan Vanhaecke; Willem Flameng; Kanigula Mubagwa; Karin R Sipido Journal: Cardiovasc Res Date: 2004-04-01 Impact factor: 10.787
Authors: H A Rockman; R S Ross; A N Harris; K U Knowlton; M E Steinhelper; L J Field; J Ross; K R Chien Journal: Proc Natl Acad Sci U S A Date: 1991-09-15 Impact factor: 11.205
Authors: C Crocini; C Ferrantini; M Scardigli; R Coppini; L Mazzoni; E Lazzeri; J M Pioner; B Scellini; A Guo; L S Song; P Yan; L M Loew; J Tardiff; C Tesi; F Vanzi; E Cerbai; F S Pavone; L Sacconi; C Poggesi Journal: J Mol Cell Cardiol Date: 2015-12-20 Impact factor: 5.000
Authors: Michael Lawless; Jessica L Caldwell; Emma J Radcliffe; Charlotte E R Smith; George W P Madders; David C Hutchings; Lori S Woods; Stephanie J Church; Richard D Unwin; Graeme J Kirkwood; Lorenz K Becker; Charles M Pearman; Rebecca F Taylor; David A Eisner; Katharine M Dibb; Andrew W Trafford Journal: Sci Rep Date: 2019-05-01 Impact factor: 4.379